Middle East Pharmaceutical Industries Company
4016.SRSAUHealthcare● Active
$62.10
$-0.20(-0.32%)
Market Cap$2.2B
P/E Ratio—
52W High$79.08572
52W Low$53.88572
Middle East Pharmaceutical Industries Company（4016.SR）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · 4016.SR · 截至 2026-06-15
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.46B | $0.39B | $0.34B | $0.30B | $0.29B |
| Cost of Revenue | $0.17B | $0.15B | $0.13B | $0.12B | $0.12B |
| Gross Profit | $0.29B | $0.24B | $0.21B | $0.18B | $0.17B |
| Gross Margin %(computed) | 62.29% | 61.77% | 61.18% | 58.70% | 58.92% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.03B | $0.02B | $0.05B | $0.04B | $0.03B |
| Total Operating Expenses | $0.18B | $0.15B | $0.13B | $0.11B | $0.09B |
| Operating Income | $0.11B | $0.09B | $0.08B | $0.07B | $0.08B |
| Operating Margin %(computed) | 23.54% | 23.11% | 23.12% | 23.24% | 26.64% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.01B | $0.01B | $0.00B |
| Income Before Tax | $0.10B | $0.09B | $0.07B | $0.07B | $0.07B |
| Income Tax Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Net Income | $0.10B | $0.08B | $0.07B | $0.06B | $0.07B |
| Net Margin %(computed) | 21.07% | 20.27% | 19.45% | 19.64% | 23.08% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.77 | $2.28 | $1.88 | $1.70 | $1.89 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B |
| EBITDA | $0.11B | $0.11B | $0.09B | $0.08B | $0.08B |
| EBITDA Margin %(computed) | 23.54% | 27.12% | 25.16% | 26.80% | 28.89% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-15 · SAR · B
深入了解Middle East Pharmaceutical Industries Company
关于Middle East Pharmaceutical Industries Company（4016.SR）损益表
Middle East Pharmaceutical Industries Company（4016.SR）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，4016.SR实现营收$0.46B，毛利润$0.29B（毛利率62.29%），净利润$0.10B（净利率21.07%）。
常见问题
4016.SR · 4 问Middle East Pharmaceutical Industries Company（4016.SR）2025财年营收为$0.46B，同比up16.9%。
4016.SR revenue4016.SR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15